Three entities, one closed loop
Capital funds the research. Research licenses therapies into the clinics. What the clinics need determines what gets funded next.
One mechanism, many indications
Outpatient neuromodulation today treats almost exclusively neuropsychiatric disease. The clinical opportunity is considerably wider than that.
Neuropsychiatric
Twenty-one million adults in the United States live with major depressive disorder, seven million of them treatment-resistant. Depression is the indication neuromodulation has proven itself on, and the foundation everything else is built from.
Major depressive disorder, generalised anxiety disorder, obsessive-compulsive disorder, suicidality
Avano will advance the global practice of medicine
We work with limited partners, clinical institutions, and neurotechnology founders building toward the same thing. If that is you, we would like to hear from you.